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Progression on ﬁrst-line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a
secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib-resistant GIST include agents that target KIT/
PDGFR with greater potency or possess broader kinase inhibition proﬁles including VEGFR. To circumvent secondary mutations in KIT/PDGFR,
inhibition of the downstream signaling in PI3K/Akt/mTOR pathway and enhanced degradation of KIT/PDGFR are also under investigation.
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INTRODUCTION
Overview of Systemic Therapy for Advanced GIST
The story of systemic therapy for advanced gastrointestinal
stromal tumors (GIST) as of now can be divided into three chapters.
The ﬁrst chapter describes an interval before the turn of the 21st century
when there were no known effective systemic therapies for this disease.
Gastrointestinal tract sarcomas, mainly GIST, demonstrated a high
rate of primary resistance to chemotherapy, low response rates, and
overall poor prognosis. Complicating matters was a lack of uniformity
in what was recognized as a GIST. The second chapter began with the
pivotal identiﬁcation of over-expression of the membrane receptor
tyrosine kinase KIT (CD117) as a unifying feature diagnostic for
a majority of GISTs. Subsequently, GIST tumors were found to have
gain-of-functionmutations inKIT [1]which fundamentally changed the
therapeutic approach to one targeting this speciﬁc kinase. Imatinib
mesylate, a selective inhibitor of KIT and PDGFR (in addition to
Bcr-Abl) was shown to lead to high rates of response and disease control
[45% response rate and 25% stable disease (SD)] with resultant
improvements in median overall survival to approximately 50 months
[2]. Since its FDA approval in 2002, imatinib has remained the standard
ﬁrst-line systemic therapy for GIST. However, over the past decade, it
has become apparent that the tale of imatinib’s success is tempered by
the observation that patients treated with imatinib are not cured nor
controlled indeﬁnitely, with median progression free survivals of <2
years reported in initial phase III trials [2,3]. Progression is primarily
attributed to the development of secondary mutations that confer resist-
ance to imatinib [4]. Thus, we enter the third chapter of theGIST story in
which the next generation of novel therapies is under development for
treatment of imatinib-resistant disease. This review will focus on those
therapies central to this most recent chapter of systemic treatment for
advanced GIST.
KIT and PDGFR Mutations
Prior to introducing the next generation of therapies, it is necessary
to ﬁrst review in greater detail the biology of GIST pathogenesis and
in particular the relationship between speciﬁc kinase mutations and
corresponding response or resistance to imatinib. Activating
mutations in the tyrosine kinases KIT (90%) and PDGFR (5%) are
responsible for development of most GISTs. The remaining small
fraction of GISTs that lack mutations in both KIT and PDGFR are
referred to as wild-type GIST. Activation of KIT or PDGFR leads to
downstream signaling in the PI3K, Ras, and Jak/Stat pathways
resulting in increased cell proliferation and inhibition of apoptosis.
Themost commonmutations inKITare found in exon 11, the regulatory
juxtamembrane (JM) domain (70%), or in exon 9, the extracellular
(EC) regulatory domain (15%). Rarely, primary mutations in KIT
occur in the kinase domains encoded by exons 13/14 for theATPbinding
domain (TK1) and exon 17 for the kinase activation loop (TK2). In
contrast, the most common primary mutations found in PDGFR are in
the kinase activation loop (TK2) encoded by exon 18, speciﬁcally the
D842V point mutation [5]. Imatinib binds to the inactive conformation
of TK1 and prevents binding of ATP. GIST tumors with exon
11 mutations are responsive to imatinib, with an objective response
rate of 72% which compares favorably to the response rate with exon
9 mutations (44%) and wild-type GIST (45%) [6]. Exon 11 mutations
also confer favorable time to disease progression (25 months) as com-
pared to exon 9mutations (17months) andwild-typeGIST (13months).
A higher dose (800 mg) of imatinib may beneﬁt patients with exon
9 mutations with a longer progression-free survival but this does not
translate to improved overall survival [7]. Primary mutations in either
TK1 or TK2 of KITare rare but do appear to still confer some sensitivity
to imatinib [7,8]. In contrast, the D842V mutation in TK2 of PDGFR
appears to be inherently resistant to imatinib. Notably,mutations in TK1
and TK2 are frequently found in GIST that has progressed on imatinib
and are thought to play a dominant role in this development of secondary
resistance to imatinib [4]. Interestingly, it has been shown that multiple
distinct mutations can develop independently within different sites
of progressing disease within a single patient [9]. Understanding
the variety, frequency, and biological signiﬁcance of these mutations
is critical to identifying novel agents that can overcome resultant
imatinib resistance.
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Sunitinib
Sunitinib (SU11248) is an oral small molecule inhibitor of multiple
receptor tyrosine kinases including KIT, PDGFR (a þ b), VEGFR
(1,2,3), FLT3, CSF-1R, and RET. Sunitinib, like imatinib, binds to
the inactive conformation of target tyrosine kinases and inhibits binding
of ATP. Despite this similarity, sunitinib has potential for activity in
imatinib-resistant disease presumably through unique binding charac-
teristics and broader spectrum of kinase inhibition including the tumor-
associated angiogenic VEGFR family of tyrosine kinases. Among the
next generation of agents for imatinib-resistant GIST, sunitinib has been
the most extensively studied. Sunitinib was tested in a double-blinded
phase III trial of 312 patients with advanced GIST intolerant or resistant
to imatinib who were randomized 2:1 to receive either sunitinib
(n ¼ 207) or placebo (n ¼ 105) [10]. Sunitinib was given at a dose
of 50 mg daily for 4 weeks followed by 2 weeks of treatment. The
primary endpoint of median time to tumor progression was signiﬁcantly
longer with sunitinib compared with placebo (6.8 vs. 1.6 months, HR
0.33, P ¼ < 0.0001). Clinical beneﬁt was obtained by 65% of patients
with 7% achieving partial response (PR) and 58% SD. After a planned
interim analysis of the ﬁrst 149 patients revealedbeneﬁtwith sunitinib in
time to tumor progression, the study was unblinded and crossover
was allowed for patients progressing on placebo. In spite of this cross-
over to active therapy, there was still a detectable improvement in
overall survival in patients receiving initial sunitinib treatment
(HR 0.49, P ¼ 0.007). Sunitinib was relatively well tolerated with
no signiﬁcant difference in discontinuation of treatment due to toxicity
between sunitinib (9%) and placebo (8%). Themost common treatment-
associated non-hematologic adverse events were fatigue, diarrhea,
hand–foot syndrome, and hypertension. There was also a signiﬁcant
difference in hematologic toxicity with greater leukopenia and
thrombocytopenia with sunitinib. Based on the observed efﬁcacy and
tolerability, sunitinibwas approved by the FDA in 2006 for patients with
GIST and progressive disease on, or intolerant to, imatinib.
Unfortunately, not all patients with imatinib-resistant GIST
beneﬁt from sunitinib. Similar to the differential sensitivity to imatinib,
sunitinib has also been shown to have variable efﬁcacy depending on the
speciﬁc mutation(s) present. Sunitinib appears to have preferential
activity against mutations involving exons 13/14 of KIT (TK1), and
less activity against mutations in the kinase activating loop (TK2)
encoded by exon 17 in KIT and exon 18 in PDGFR (D842V)
[11,12]. While sunitinib is the current standard of care for second line
therapy of imatinib-resistant disease, there is an obvious need for
additional therapeutic options to treat patients whose disease is not
controlled with sunitinib or imatinib.
NEW TKI’S THAT INHIBIT KITAND PDGFR
In this section, we describe three of the next generation agents which
are similar to imatinib in that that they targetKITand PDGFR, but do not
target VEGFR like sunitinib.
Nilotinib
Nilotinib (AMN107) is an orally delivered small molecule inhibitor
of KIT, PDGFRa, and Bcr-Abl, similar to imatinib and sunitinib in that
it also binds the inactive conformation of target tyrosine kinases.
Despite a similar target kinase inhibition proﬁle to imatinib, nilotinib
exhibits enhanced cellular uptakewhich results in a sevenfold to tenfold
higher intracellular concentration than imatinib [13]. A phase I
study demonstrated clinical activity of nilotinib in patients with
imatinib-resistant GIST with 14 out of 18 patients achieving either
PR (1) or SD (13) and a median progression-free survival of 5.5 months
[14]. A retrospective analysis was performed on 52 consecutive patients
who failed both imatinib and sunitinib and were then treated with
nilotinib given 400 mg twice daily [15]. Five patients (10%) beneﬁtted
from nilotinibwith objective response (1 CR, 4 PR) and an additional 19
patients (37%) achieved stability of disease for a 47% clinical beneﬁt
rate. Median progression-free survival was 3 months with a median
overall survival of 8.5months. A phase II trial further conﬁrmed activity
of nilotinib in the third-line setting with 35 patients enrolled and
24 patients (69%) demonstrating beneﬁt (1PR and 23 SD)with amedian
progression-free survival of 4 months and median overall survival of
11 months [16]. A phase III trial was conducted in 248 patients who had
failed both imatinib and sunitinib randomized 2:1 to either nilotinib or
best supportive care [17]. There was no statistical difference in the
intent-to-treat population for progression-free survival or overall sur-
vival. However, one potential confounding factor in the results of this
study was allowance of patients on the best supportive care arm to
continue to receive imatinib or sunitinib as the majority did (93%).
An exploratory analysis of 197 patients (79%) receiving treatment as
true third line (excluded patients who received more than two prior
regimens) demonstrated a longer survival with nilotinib (14.5 vs. 10
months, P ¼ 0.02). Overall, nilotinib appeared to be well tolerated
in the studies above with no difference in adverse events between
the two arms of the phase III trial. Treatment-related adverse events
were noted to most commonly include anorexia, nausea and vomiting,
and diarrhea. In an attempt to assess whether nilotinib might have
more activity in untreated patients, nilotinib was tested in a phase II
study of 19 treatment-naı¨ve patients with advanced metastatic
disease. Preliminary analysis of 14 patients who completed 6 months
of therapy revealed beneﬁt in 12 patients with either PR (43%) or SD
(43%) [18].
The preliminary results of these studies do not include comprehen-
sive analysis of mutation status at time of treatment with nilotinib and
therefore it is difﬁcult to hypothesize incorporation of a risk-adaptive
strategy for nilotinib. Nevertheless, the range of beneﬁt achieved in the
third line setting suggests nilotinib may provide beneﬁt to some portion
of patients despite secondary mutations that confer resistance to ima-
tinib and sunitinib.
Masitinib
Masitinib (AB1010) is an orally administered small molecule
inhibitor of KIT, PDGFR (a þ b), and Lyn [19]. Preclinical evaluation
of masitinib demonstrated inhibition of mutations in exon 11 (JM) and
wild-type KIT but not the D816Vmutation in exon 17 (TK2). A phase 1
study of masitinib for patients with solid tumors included 19 patients
with imatinib resistant or intolerant GIST and clinical beneﬁt was
achieved in seven of those patients (1 PR and 6 SD) [20]. Based on
pharmacokinetic data from this phase I study, a weight adjusted dosing
was tested in a phase II study of masitinib in the ﬁrst-line treatment of
30 patients with advanced GIST. Twenty-nine patients (96.7%)
achieved disease control with 1 CR, 15 PR, and 13 SD [21]. A promising
median progression-free survival of 41.3 months yielded a 3-year
survival rate of 89.9%. Notable toxicities included asthenia, diarrhea,
nausea and vomiting, muscle spasms, rash, and abdominal pain.
A majority of patients also experienced treatment-related edema. Rates
of hematologic events were low (13% anemia and 17% neutropenia)
compared to imatinib. Furthermore, masitinib’s selective inhibition of
KIT and PDGFR but not Abl kinase was hypothesized to cause less
cardiotoxicity than imatinib and, at least in this small study, there were
no reports of cardiotoxicity with masitinib. Based on the high rate of
response and sustained beneﬁt in this phase II trial of untreated advanced
GIST, masitinib is a potential candidate to compare with imatinib in
future ﬁrst-line therapy trials. Efﬁcacy of masitinib in patients
previously treated with imatinib or other agents has not been studied
other than the phase I study described above.
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Dasatinib
Dasatinib (BMS-3548245) is an oral small molecule which potently
not only inhibits Bcr-Abl and the Src family of kinases but also inhibits
KIT and PDGFR. Unlike the previously described tyrosine kinase
inhibitors which bind the inactive conformation, dasatinib binds to
the active conformation [22]. This unique characteristic is thought to
explain the ability of dasitinib to inhibit the PDGFR mutation D842V
found in the kinase activation loop (TK2) which stabilizes the kinase in
the active conformation [23,24]. A phase II trial in the United States
investigating dasatinib in sarcomas including GIST is ongoing.
Additionally, a phase II study in Switzerland is investigating efﬁcacy
of dasatinib as ﬁrst-line treatment for GIST. Analysis of the results of
these trials will hopefully detail, speciﬁc efﬁcacy in patients with
PDGFR D842V mutation for whom other kinase inhibitors have been
ineffective.
TKI’S THAT INHIBIT KIT/PDGFR AND VEGFR
Whereas the three previously described kinase inhibitors
(nilotinib, masitinib, and dasatinib) are similar to imatinib in that they
target KIT and PDGFR, they are unlike sunitinib in that they do not
target VEGF(R).Wewill next describe a series of novel therapies which
are similar to sunitinib and target VEGF in addition to KITand PDGFR.
GIST tumors are highly vascular and angiogenesis has been suggested to
play a signiﬁcant role in tumor progression. IncreasedVEGF expression
and high micro-vessel density have been shown to correlate with
prognosis [25,26]. Targeting angiogenesis in combination with KIT
or PDGFR inhibition is thus hypothesized to improve on efﬁcacy
achieved with inhibition of KIT/PDGFR only.
Sorafenib
Sorafenib (BAY 43-9006) is a small molecule given orally that
inhibits the serine/threonine Raf kinases but also has activity
against the tyrosine kinases KIT, PDGFRb, VEGFR(2,3), Flt3, and
Ret. Sorafenib was shown in preclinical testing to inhibit wild-type KIT
and PDGFR as well as mutation T670I found in exon 14 of KIT (TK1)
[27]. It appeared to have less activity against an imatinib-resistant
mutation found in the kinase activation loop (TK2). Preliminary results
of a phase II trial in 26 patients in whom disease progressed on both
imatinib and sunitinib revealed a clinical beneﬁt rate of 71% with 3 PR
(13%) and 14 SD (58%) [28]. Median progression-free survival was 5.3
months with a 13-monthmedian survival. Sorafenib appeared to bewell
tolerated with the most frequent grade 3 toxicities being hand–foot
syndrome and hypertension. A retrospective study of sorafenib given to
32 patients in the fourth line setting after progression on imatinib,
sunitinib and nilotinib also demonstrated activity in heavily pre-treated
patients [29]. Clinical beneﬁt rate was 63% with 19% PR and 44% SD
with amedian progression-free survival of 5months andmedian overall
survival of 10.5months.Mutational analysis has not yet been reported in
this advanced setting but the results are nevertheless encouraging based
on efﬁcacy despite a presumption of mutations conferring resistance to
prior therapies.
Motesanib
Motesanib (AMG 706) is another small molecule given orally that
potently inhibits VEGFR (1,2,3) and KITand to a lesser degree inhibits
RETand PDGFR [30].Motesanib binds the inactive conformation of the
ATP-binding domain (JM) similar to imatinib. However, preclinical
evaluation demonstratedmotesanib has greater potency than imatinib in
inhibiting the common primary KIT mutations found in exons 11 (JM)
and 9 (EC) [31]. In addition, motesanib appears to have activity against
wild-type KIT, secondary mutations in the ATP-binding domain (TK1),
and even amutation found in the kinase activation loop (TK2)Y823D. It
does not appear, however, to inhibit the D816V kinase activation loop
(TK2) mutation. Like the other multi-kinase inhibitors in this group that
also target VEGFR, motesanib has the potential to augment the clinical
beneﬁt of inhibitingKITor PDGFRby also inhibiting angiogenesis. The
anti-angiogenic properties of motesanib were shown to contribute to
reduction in tumor growth in a preclinical xenograft model of breast
cancer through decrease in neovascularization [32]. Based on this
preclinical data and a phase I study in solid malignancies establishing
a daily dose of 125 mg of motesanib, a phase II study in the second line
setting was completed for patients with advanced GISTwho had failed
imatinib [33]. Clinical beneﬁt was achieved in 62% of 102 evaluable
patients with 3% achieving PR and 59% SD (14% durable SD > 6
months). Median progression-free survival was a modest 4 months.
Patients not uncommonly discontinued treatment (27%) as a result of an
adverse event, with the most common grade 3 toxicities noted as
hypertension, fatigue, and diarrhea. No mutational analysis has been
reported and it is possible that motesanib may have utility in GISTwith
speciﬁc mutations such as the Y823D mutation (TK2).
Vatalanib
Vatalanib (PTK787/ZK222584) is a small molecule multi-kinase
inhibitor given orally, which like motesanib, potently inhibits VEGFR
(1,2,3) and to a lesser degree KIT and PDGFRb [34]. Nevertheless,
given its potential dual activity against both KIT/PDGFR and
VEGFR, like the other agents in this group, it has been studied for
potential efﬁcacy in GIST. A small phase II study evaluated vatalanib in
the second line setting, treating 15 patients with imatinib-resistant
advanced GIST [35]. Vatalanib appeared to have moderate activity with
two patients achieving a PR and eight patients maintaining SD for over
3 months for a clinical beneﬁt rate of 67% and a median time to
progression of 8.5 months. Vatalanib was dosed once daily at
1250 mg and was reportedly well tolerated with no treatment related
grade 3 or 4 toxicities. A larger phase II study of vatalanib in the
third line setting for patients with GIST refractory to both imatinib
and sunitinib is currently in progress. At this time, there is no
information available about any potential selective inhibition of
speciﬁc mutations in KIT and PDGFR.
Bevacizumab
Bevacizumab is a monoclonal antibody which affects angiogenesis
by binding circulating VEGF with subsequent inhibition of VEGF
signaling. Unlike the other agents in this section, it does not
directly target tyrosine kinases. Based on the same theoretical rationale
as described for the multi-kinase inhibitors, bevacizumab was proposed
for use in combination with imatinib to augment the clinical beneﬁt
achieved with KIT/PDGFR inhibition by also targeting angiogenesis.
A phase III trial was initiated randomizing patients with advanced
GIST to imatinib with or without bevacizumab. Accrual to this trial
has been slow and no results have been reported to date.
INDIRECT INHIBITORS
All of the above agents except bevacizumab share a common
feature in that they are direct tyrosine kinase inhibitors which
target KIT and PDGFR. Some of the more promiscuous agents also
target other pathways such as angiogenesis through inhibition of
VEGFRs, as well as other kinases like Src and Raf. It is reasonable
to hypothesize that the previously described novel agents have different
binding characteristics and inhibition of other pathways may have
resulted in the variable efﬁcacy in treating resistance to imatinib by
circumventing primary and secondary mutations in KIT and PDGFR.
An alternative approach under active investigation is an attempt to
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nullify sensitivity of speciﬁc mutations to inhibition by targeting the
kinase indirectly either through enhanced degradation of the kinase or
targeting downstream pathways activated by KIT/PDGFR.
Hsp-90 Inhibition
Hsp90 functions as a chaperone protein which protects client
proteins from ubiquitination and degradation. Both KIT and PDGFR
have been shown to depend on Hsp90 for stabilization [36,37]. This
dependence has been demonstrated in preclinical evaluation to be a
target that can be exploited for inhibition of KIT and PDGFR despite
mutations in TK1 and TK2 [24,38]. The documented inhibition of KIT
and PDGFR with mutations in TK2, KIT D816V, and PDGFR D842V,
are particularly notable as these mutations confer resistance to all the
above kinase inhibitors with the exception of dasatanib. Thus, based on
preclinical data, inhibition of Hsp90 appears to have potential broad
utility in imatinib-resistant GIST.
IPI-504. The novel Hsp90 inhibitor IPI-504 has been tested in a
phase I study of 38 patients with metastatic GIST resistant to imatinib
and sunitinib (95%) as well as additional prior agents (38%) [39]. An
encouraging 78% of 37 evaluable patients achieved a best response of
SD, although there were no partial or complete responses. Treatment
was reportedly well tolerated in this phase I study with a deﬁned
MTD of 400 mg/m2 given IV twice weekly for 2 weeks followed by
1 week of rest. Mutational analysis of KIT and PDGFR in patients
treated with IPI-504 in this study has not been reported. This type of
analysis is needed to conﬁrm the hypothesized beneﬁt of this strategy for
patients with disease driven by mutations otherwise refractory to direct
tyrosine kinase inhibitors.
PI3K/AKT/mTOR Pathway Inhibition
Growth factor activation of the PI3K/AKT/mTOR pathway has been
shown to play a physiologic role in cell proliferation. Dysregulation
of this pathway in cancer leads to proliferation of cancer cells and has
therefore been targeted in multiple malignancies. The PI3K/AKT/
mTOR pathway is downstream of the receptor tyrosine kinases KIT
and PDGFR which are constitutively activated in GIST. It has been
hypothesized that targeting a downstream effector pathway of KIT and
PDGFR could augment efﬁcacy in treatment of GIST. Preclinical
results from combining imatinib with inhibitors of the PI3K/AKT/
mTOR pathway suggested a potential synergy in promoting apoptosis
in imatinib-resistant GIST [40]. This result led to the trials below
combining imatinib with either inhibitors of Akt or mTOR.
Perifosine. Perifosine (KRX0401) is an oral alkylphospholipid
that inhibits Akt phosphorylation by preventing its translocation to
the cell membrane [41]. A phase II study investigated the activity
of perifosine in combination with imatinib in 40 patients with
imatinib-refractory disease [42]. Patients were randomly assigned to
two different dosing schedules of perifosine, either 100 mg daily or
900 mg dose given weekly. Of the 36 patients evaluable for response,
44% achieved SD but no patient achieved a deﬁned partial or complete
response. This result translated to a median progression-free survival
of only 2.2 months although overall survival was 18.3 months. Notably,
four out of ﬁve patients with wild-type KIT achieved SD suggesting
potential beneﬁt of targeting the PI3K/AKT/mTOR pathway in wild-
type GIST. Interestingly, it was recently reported that insulin-like
growth factor 1 receptor (IGF-1R) which signals through the PI3K/
AKTpathway is over-expressed inGIST tumorswithwild-typeKITand
PDGFR [43]. This provides a mechanistic explanation for the potential
speciﬁc efﬁcacy of Akt inhibition with perifosine in wild-type GIST.
The combination of perifosine and imatinib did incur moderate toxicity,
but only three (8%) patients were removed from the study for toxicity,
with the most common grade 3 event fatigue occurring in 20%.
These preliminary results suggest potential activity of combining
Akt inhibition with imatinib to overcome resistance, particularly in
wild-type GIST. However, the short median progression-free survival
suggests less clinical beneﬁt from combining perifosine with imatinib
in imatinib-resistant disease than one may have thought based on the
preclinical data. In order to better assess whether Akt inhibition can
synergizewith KIT/PDGFR inhibition to overcome imatinib resistance,
it may be necessary to study perifosine in combination with one of the
next generation tyrosine kinase inhibitors.
Everolimus. Downstream of PI3K and Akt is the intracellular
kinase, mammalian target of rapamycin (mTOR) which helps regulate
response to growth factors as well as signals of cellular stress. Ever-
olimus (RAD001) is an oral mTOR inhibitor which has been studied in
combination with imatinib for patients with GIST. A phase II study
tested this combination in two groups of patients, 28 patients who
progressed on imatinib only (second line) and 47 patients who pro-
gressed on imatinib and either sunitinib or another tyrosine kinase
inhibitor (third line) [44]. In patients treated in the second line setting,
36% achieved a best response of SD yielding a disappointing 1.9-month
progression-free survival but a median overall survival of 14.9 months.
For patients treated in the third line setting, 2% had a PR and 43% had
SD resulting in 3.5-monthmedian progression-free survival andmedian
overall survival of 10.7 months. Grades 3 and 4 adverse events were
experienced by 67% of treated patients with the most common noted to
be hypokalemia, anemia, vomiting, and fatigue. A second phase II study
investigated this same combination of everolimus and imatinib in 27
patients in the second line setting after progression on imatinib [45].
Results of this study were similar to the prior study with 33% achieving
SD as a best response and no objective responses. These results
demonstrate a modest beneﬁt of adding mTOR inhibition to
imatinib in imatinib-refractory disease. The mutational status of KIT
and PDGFR was not reported in the above studies with everolimus
TABLE I. Systemic Therapy for Gastrointestinal Stromal Tumors
Category Agent Molecular target Comments
Inhibits KIT/PDGFR Imatinib KIT, PDGFRa þ b, Bcr-Abl Used first line in advanced disease Effective as adjuvant treatment
Nilotinib KIT, PDGFRa, Bcr-Abl Second generation imatinib Increased intracellular concentration
Masitinib KIT, PDGFRa þ b, Lyn High specificity for KIT and PDGFR
Dasatinib KIT, PDGFR, Bcr-Abl, Src Binds active conformation KIT/PDGFR unlike other TKI’s
Inhibits KIT/PDGFR
and angiogenesis
Sunitinib KIT, PDGFR, VEGFR (1,2,3),
FLT3, CSF-1R, RET
FDA approved for second line therapy May be preferred first
line for exon 9 KIT mutations
Sorafenib KIT, PDGFRb, VEGFR(2,3), Flt3, Ret Broad kinase inhibition profile
Motesanib KIT, PDGFR, VEGFR(1,2,3), Ret Potent VEGFR inhibitor
Vatalanib KIT, PDGFRb, VEGFR(1,2,3) Less active against KIT/PDGFR
Indirect inhibitors IPI-504 Hsp90 Promotes degradation of KIT/PDGFR Independent of specific
kinase primary and secondary mutations
Perifosine Akt Inhibits downstream of KIT/PDGFR
Everolimus mTOR Inhibits downstream of KIT/PDGFR
904 Kim and Zalupski
Journal of Surgical Oncology
and thus it remains unknown whether there may be any mutational
dependence or selectivity for response to the addition of mTOR
inhibition.
CONCLUSION
At the present time, imatinib and sunitinib remain the standard ﬁrst
and second line therapies for patients with advanced GIST. This review
highlights multiple new tyrosine kinase inhibitors with potential utility
when standard options have failed (Table I). As more experience and
information is obtained for each of the described next generation agents,
it is necessary to develop better understanding of the sensitivity of
speciﬁc mutations to speciﬁc agents. Obtaining a complete proﬁle of
mutations in GIST tumors treated in clinical trials with novel agents is
critical. This information is required to begin to consider applying
genotyping to a risk-adaptive strategy with assignment of speciﬁc
therapeutic options based on an individual patient’s tumor mutation
proﬁle to ultimately provide personally tailored targeted therapy. One
might hypothesize newer agents that potentially circumvent-speciﬁc
mutations (e.g., inhibition ofHsp90)may play a critical role in salvaging
patients who are refractory to direct tyrosine kinase inhibition. One can
also imagine that combining these types of agents in an earlier line of
therapy may lead to a more meaningful response of longer duration by
eliminating selective pressure for development of secondary mutations.
We are still very early in this third chapter of the story of systemic
therapy for GIST. Preliminary efforts and trial results provide promise
and encouragement for how this chapter of the story will ultimately
unfold for patients with advanced GIST.
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